Susan Moran
Direttore/Membro del Consiglio presso BIOATLA, INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Susan Moran
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOATLA, INC. | Direttore/Membro del Consiglio | 01/12/2020 | - |
Independent Dir/Board Member | 01/12/2020 | - | |
TYRA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 07/05/2024 | - |
Independent Dir/Board Member | 07/05/2024 | - |
Storia della carriera di Susan Moran
Precedenti posizioni note di Susan Moran
Società | Posizione | Inizio | Fine |
---|---|---|---|
RAYZEBIO, INC. | Direttore Tecnico/Scientifico/R&S | 01/07/2021 | 01/05/2024 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Direttore Tecnico/Scientifico/R&S | 01/03/2018 | 01/06/2021 |
PUMA BIOTECHNOLOGY, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2014 | 01/02/2018 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2011 | 01/01/2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 01/01/2007 | 01/01/2011 |
Formazione di Susan Moran
University of Virginia | Undergraduate Degree |
University of Pennsylvania Medical Center | Graduate Degree |
Duke University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 10 |
Regno Unito | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Settori
Health Technology | 8 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 4 |
---|---|
BIOATLA, INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
TYRA BIOSCIENCES, INC. | Health Technology |
Aziende private | 3 |
---|---|
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Susan Moran
- Esperienza